Veelken H - Search Results

1

Immunotherapy with dendritic cells for prostate cancer.

Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H. Thomas-Kaskel AK, et al. Among authors: veelken h. Int J Cancer. 2007 Aug 1;121(3):467-73. doi: 10.1002/ijc.22859. Int J Cancer. 2007. PMID: 17514654 Review.

2

[Active immunotherapy of prostate cancer with a focus on dendritic cells].

Thomas-Kaskel AK, Veelken H. Thomas-Kaskel AK, et al. Among authors: veelken h. Actas Urol Esp. 2007 Jun;31(6):668-79. doi: 10.1016/s0210-4806(07)73704-x. Actas Urol Esp. 2007. PMID: 17896564 Review. Spanish.

3

Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.

Bertinetti C, Zirlik K, Heining-Mikesch K, Ihorst G, Dierbach H, Waller CF, Veelken H. Bertinetti C, et al. Among authors: veelken h. Cancer Res. 2006 Apr 15;66(8):4496-502. doi: 10.1158/0008-5472.CAN-05-4233. Cancer Res. 2006. PMID: 16618777 Clinical Trial.

4

Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.

Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H. Thomas-Kaskel AK, et al. Among authors: veelken h. Int J Cancer. 2006 Nov 15;119(10):2428-34. doi: 10.1002/ijc.22097. Int J Cancer. 2006. PMID: 16977630 Clinical Trial.

5

Dendritic-cell vaccination for prostate cancer.

Thomas-Kaskel AK, Veelken H. Thomas-Kaskel AK, et al. Among authors: veelken h. Immunotherapy. 2009 Jan;1(1):63-72. doi: 10.2217/1750743X.1.1.63. Immunotherapy. 2009. PMID: 20635974 Review.

6

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer.

Veelken H, Mackensen A, Lahn M, Köhler G, Becker D, Franke B, Brennscheidt U, Kulmburg P, Rosenthal FM, Keller H, Hasse J, Schultze-Seemann W, Farthmann EH, Mertelsmann R, Lindemann A. Veelken H, et al. Int J Cancer. 1997 Jan 27;70(3):269-77. doi: 10.1002/(sici)1097-0215(19970127)70:3<269::aid-ijc4>3.0.co;2-v. Int J Cancer. 1997. PMID: 9033626 Clinical Trial.

7

Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes.

Thomas-Kaskel AK, Portugal TG, Herchenbach D, Houet L, Veelken H, Finke J. Thomas-Kaskel AK, et al. Among authors: veelken h. Acta Haematol. 2007;117(4):226-35. doi: 10.1159/000099547. Epub 2007 Feb 14. Acta Haematol. 2007. PMID: 17308369

8

Active immunotherapy of multiple myeloma.

Houet L, Veelken H. Houet L, et al. Among authors: veelken h. Eur J Cancer. 2006 Jul;42(11):1653-60. doi: 10.1016/j.ejca.2006.03.008. Epub 2006 Jun 22. Eur J Cancer. 2006. PMID: 16797966 Review.

9

Active immunotherapy in follicular lymphoma.

Veelken H. Veelken H. Semin Cancer Biol. 2003 Jun;13(3):241-7. doi: 10.1016/s1044-579x(03)00020-8. Semin Cancer Biol. 2003. PMID: 12959355 Review.

10

Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.

Moeller I, Spagnoli GC, Finke J, Veelken H, Houet L. Moeller I, et al. Among authors: veelken h. Cancer Immunol Immunother. 2012 Nov;61(11):2079-90. doi: 10.1007/s00262-012-1272-y. Epub 2012 May 6. Cancer Immunol Immunother. 2012. PMID: 22562379 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters